Entresto(sacubitril)
Entresto, Neparvis, Sacubitril / Valsartan (sacubitril) is a small molecule pharmaceutical. Sacubitril was first approved as Entresto on 2015-07-07. It has been approved in Europe to treat heart failure.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
Combinations
Entresto, Sacubitril valsartan
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| entresto | New Drug Application | 2024-07-22 |
| sacubitril and valsartan | ANDA | 2024-12-10 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| heart failure | HP_0001635 | D006333 | I50 |
| diabetic nephropathies | EFO_0000401 | D003928 | — |
| hypertension | EFO_0000537 | D006973 | I10 |
| left ventricular dysfunction | — | D018487 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
SACUBITRIL / VALSARTAN, ENTRESTO, NOVARTIS PHARMS CORP | |||
| 2024-02-16 | M-82 | ||
HCPCS
No data
Clinical
Clinical Trials
199 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | HP_0001635 | I50 | 4 | 18 | 19 | 43 | 43 | 123 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | 14 | 14 | 6 | 5 | 38 |
| Essential hypertension | D000075222 | — | I10 | — | 5 | 6 | 1 | 1 | 13 |
| Systolic heart failure | D054143 | EFO_1001207 | I50.20 | — | — | 1 | 4 | 4 | 9 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 1 | 4 | 3 | 1 | 9 |
| Infarction | D007238 | EFO_0009463 | — | — | 1 | 4 | 2 | 1 | 8 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 3 | 1 | 1 | 2 | 6 |
| Left ventricular dysfunction | D018487 | — | — | — | 1 | 2 | 1 | 1 | 5 |
| Hypertrophy | D006984 | EFO_0002460 | — | — | 4 | 1 | 1 | — | 5 |
| Systolic murmurs | D054160 | — | R01.1 | — | 1 | 2 | 1 | 1 | 5 |
Show 36 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ventricular remodeling | D020257 | — | — | — | 2 | 2 | — | 3 | 7 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | 3 | 3 | — | — | 5 |
| Hypertrophic cardiomyopathy | D002312 | EFO_0000538 | I42.1 | — | 3 | 1 | — | — | 3 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 2 | 1 | — | 1 | 3 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | 1 | 1 | — | — | 3 |
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | — | 1 | — | 1 | 2 |
| St elevation myocardial infarction | D000072657 | — | — | — | — | 2 | — | — | 2 |
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | — | 1 | 1 | — | 1 | 2 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | — | 1 | — | — | 1 |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | — | — | 1 | — | — | 1 |
Show 7 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | 1 | — | — | — | 3 |
| Atrial remodeling | D064752 | — | — | — | 1 | — | — | 1 | 2 |
| Covid-19 | D000086382 | — | — | 1 | 1 | — | — | 1 | 2 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 2 | — | — | — | 2 |
| Diastolic heart failure | D054144 | EFO_1000899 | I50.30 | — | 2 | — | — | — | 2 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | 2 | — | — | — | 2 |
| Chronic renal insufficiency | D051436 | — | N18 | 2 | 1 | — | — | — | 2 |
| Myositis | D009220 | EFO_0000783 | G72.49 | — | 1 | — | — | — | 1 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | 1 | — | — | — | 1 |
| Insulin resistance | D007333 | HP_0000855 | — | — | 1 | — | — | — | 1 |
Show 13 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 1 | — | — | — | — | 1 |
| Papillary thyroid cancer | D000077273 | — | — | 1 | — | — | — | — | 1 |
| Thyroid diseases | D013959 | HP_0000820 | E00-E07 | 1 | — | — | — | — | 1 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Frailty | D000073496 | — | R53.1 | — | — | — | — | 1 | 1 |
| Hematopoietic stem cell transplantation | D018380 | — | — | — | — | — | — | 1 | 1 |
| Hyperkalemia | D006947 | HP_0002153 | E87.5 | — | — | — | — | 1 | 1 |
| Cardio-renal syndrome | D059347 | — | — | — | — | — | — | 1 | 1 |
| Lymphoma | D008223 | — | C85.9 | — | — | — | — | 1 | 1 |
| Univentricular heart | D000080039 | — | Q20.4 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sacubitril |
| INN | sacubitril |
| Description | Sacubitril is a member of biphenyls. |
| Classification | Small molecule |
| Drug class | endopeptidase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 149709-62-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3137301 |
| ChEBI ID | — |
| PubChem CID | 9811834 |
| DrugBank | DB09292 |
| UNII ID | 17ERJ0MKGI (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Entresto – Novartis
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Sacubitril
+
Valsartan
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,426 documents
View more details
Safety
Black-box Warning
Black-box warning for: Entresto, Sacubitril and valsartan
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
109,861 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use